Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asacaine
- Development stage
- Phase 1
- Lead developer
- Auxesis Pharma
- Administration
- Topical
01
Overview
**Asacaine** is an investigational topical analgesic being developed by Auxesis Pharma for localized skin pain and irritation. It is being evaluated in a first-in-human Phase 1 study in healthy volunteers with ultraviolet B-induced skin pain, assessing safety, local tolerability, pharmacokinetics, and pharmacodynamics following topical application. Public trial materials do not disclose Asacaine's precise chemical composition or molecular target.
- Other names
- asacaine
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on asacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asacaine.